Ocular Therapeutix Inc.

Ocular Therapeutix employs bioresorbable hydrogel technology to treat retinal and ocular diseases; with FDA‑approved DEXTENZA, Phase III AXPAXLI for wet AMD, and growing pipeline, it targets high‑growth eye‑care markets.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Physicians

Employees: 274
HQ: Bedford

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
OCUL	Ocular Therapeutix Inc. Cap: 2.4B	EQUITY	NMS	USD	US67576A1007	Active	📈